PDF herunterladen
Semin intervent Radiol 2014; 31(01): 091-097
DOI: 10.1055/s-0033-1363848
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Immunologics and Chemotherapeutics for Renal Cell Carcinoma

Elan Diamond
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
,
Jamie Riches
2   Department of Medicine, St. Luke's-Roosevelt Hospital Center, New York, New York
,
Bishoy Faltas
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
,
Scott T. Tagawa
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
,
David M. Nanus
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. Februar 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Treatment of metastatic renal cell carcinoma remains a challenge for clinicians. Traditional chemotherapy is ineffective and immunotherapy with interleukin-2 is only occasionally beneficial. The development of numerous agents targeting vascular endothelial growth factor and mammalian target of rapamycin signaling pathways that have been studied in phase III trials have resulted in significant improvement in survival for patients with clear cell renal cell carcinoma. Currently available U.S. Food and Drug Administration-approved first line targeted agents include sunitinib, pazopanib, temsirolimus, and bevacizumab (with interferon), while axitinib, everolimus, and sorafenib are most extensively used following progression as second- or third line therapy. Attempts to augment the activity of these agents by combining them together or with chemotherapy or immunotherapy have not yet proven to improve outcomes. As a result, the sequential use of single agents remains the current standard of care.

Keywords

chemotherapy - renal cell carcinoma - VGEF inhibitors - mTOR inhibitors - interleukin-2 - interventional radiology
 

  • References

  • 1 Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol 2006; 8 (1) 1-7
    PubMedGoogle Scholar
  • 2 SEER Cancer Statistics Review, 1975–2010. In: Howlader N, Noone A, Krapcho M. , et al, eds. Bethesda, MD: National Cancer Institute; 2013 . Available at: http://seer.cancer.gov/csr/1975_2010/ . Accessed June 12, 2013
    PubMedGoogle Scholar
  • 3 Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (3, Suppl) 1098-1109
    CrossrefPubMedGoogle Scholar
  • 4 Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1) CD001425
    PubMedGoogle Scholar
  • 5 Pyrhönen S, Salminen E, Ruutu M , et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17 (9) 2859-2867
    PubMedGoogle Scholar
  • 6 Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13 (3) 688-696
    PubMedGoogle Scholar
  • 7 Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl. 01) S55-S57
    PubMedGoogle Scholar
  • 8 McDermott DF, Ghebremichael MS, Signoretti S , et al. The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol ASCO Annual Meeting Abstracts 2010; 28 (15, Suppl): 4514
    PubMedGoogle Scholar
  • 9 McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007; 13 (2 Pt 2) 716s-720s
    CrossrefPubMedGoogle Scholar
  • 10 Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012; 33 (1) 9-16
    PubMedGoogle Scholar
  • 11 Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22 (24) 4991-5004
    CrossrefPubMedGoogle Scholar
  • 12 Tory K, Brauch H, Linehan M , et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989; 81 (14) 1097-1101
    CrossrefPubMedGoogle Scholar
  • 13 Yang JC, Haworth L, Sherry RM , et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5) 427-434
    CrossrefPubMedGoogle Scholar
  • 14 Escudier B, Bellmunt J, Négrier S , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28 (13) 2144-2150
    CrossrefPubMedGoogle Scholar
  • 15 Rini BI, Halabi S, Rosenberg JE , et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28 (13) 2137-2143
    CrossrefPubMedGoogle Scholar
  • 16 Escudier B, Eisen T, Stadler WM , et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27 (20) 3312-3318
    CrossrefPubMedGoogle Scholar
  • 17 Escudier B, Szczylik C, Hutson TE , et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (8) 1280-1289
    CrossrefPubMedGoogle Scholar
  • 18 Hutson TE, Lesovoy V, Al-Shukri S. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013; 14 (Suppl. 13) 1287-1294
    CrossrefPubMedGoogle Scholar
  • 19 Motzer RJ, Michaelson MD, Redman BG , et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (1) 16-24
    CrossrefPubMedGoogle Scholar
  • 20 Motzer RJ, Rini BI, Bukowski RM , et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295 (21) 2516-2524
    CrossrefPubMedGoogle Scholar
  • 21 Motzer RJ, Hutson TE, Tomczak P , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (22) 3584-3590
    CrossrefPubMedGoogle Scholar
  • 22 Dudek AZ, Raza A, Chi M , et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 2013; 11 (2) 155-160
    CrossrefPubMedGoogle Scholar
  • 23 Motzer RJ, Hutson TE, Olsen MR , et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30 (12) 1371-1377
    CrossrefPubMedGoogle Scholar
  • 24 Hutson TE, Davis ID, Machiels JP , et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28 (3) 475-480
    CrossrefPubMedGoogle Scholar
  • 25 Sternberg CN, Davis ID, Mardiak J , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (6) 1061-1068
    CrossrefPubMedGoogle Scholar
  • 26 Motzer RJ, Hutson TE, Cella D , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369 (8) 722-731
    CrossrefPubMedGoogle Scholar
  • 27 Rixe O, Bukowski RM, Michaelson MD , et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8 (11) 975-984
    CrossrefPubMedGoogle Scholar
  • 28 Rini BI, Wilding G, Hudes G , et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (27) 4462-4468
    CrossrefPubMedGoogle Scholar
  • 29 Rini BI, Escudier B, Tomczak P , et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378 (9807) 1931-1939
    CrossrefPubMedGoogle Scholar
  • 30 Rini BI, Melichar B, Ueda T , et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013; 14: 1233-1242
    CrossrefPubMedGoogle Scholar
  • 31 Hudes G, Carducci M, Tomczak P , et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356 (22) 2271-2281
    CrossrefPubMedGoogle Scholar
  • 32 Dutcher JP, de Souza P, McDermott D , et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26 (2) 202-209
    CrossrefPubMedGoogle Scholar
  • 33 Hutson TE, Escudier B, Esteban E , et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2013;
    PubMedGoogle Scholar
  • 34 Motzer RJ, Escudier B, Oudard S , et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372 (9637) 449-456
    CrossrefPubMedGoogle Scholar
  • 35 Kuebler JP, Hogan TF, Trump DL, Bryan GT. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep 1984; 68 (6) 925-926
    PubMedGoogle Scholar
  • 36 Hrushesky WJ, von Roemeling R, Lanning RM, Rabatin JT. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990; 8 (9) 1504-1513
    PubMedGoogle Scholar
  • 37 Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002; 95 (8) 1629-1636
    CrossrefPubMedGoogle Scholar
  • 38 George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 2002; 13 (1) 116-120
    PubMedGoogle Scholar
  • 39 Bennouna J, Delva R, Gomez F , et al. A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology 2003; 64 (1) 25-27
    CrossrefPubMedGoogle Scholar
  • 40 Haas NB, Lin X, Manola J , et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012; 29 (2) 761-767
    CrossrefPubMedGoogle Scholar
  • 41 Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101 (7) 1545-1551
    CrossrefPubMedGoogle Scholar
  • 42 Fosså SD, Raabe N, Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study. Br J Urol 1989; 64 (5) 468-471
    CrossrefPubMedGoogle Scholar
  • 43 Rizzo M, Bartoletti R, Selli C, Sicignano A, Criscuolo D. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma. Eur Urol 1989; 16 (4) 271-277
    PubMedGoogle Scholar
  • 44 Neidhart JA, Anderson SA, Harris JE , et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9 (5) 832-836
    PubMedGoogle Scholar
  • 45 Pyrhönen S, Salminen E, Ruutu M , et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17 (9) 2859-2867
    PubMedGoogle Scholar
  • 46 Ellerhorst JA, Sella A, Amato RJ , et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997; 80 (11) 2128-2132
    CrossrefPubMedGoogle Scholar
  • 47 Kirchner GI, Franzke A, Buer J , et al. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol 1998; 46 (1) 5-10
    PubMedGoogle Scholar
  • 48 Joffe JK, Banks RE, Forbes MA , et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996; 77 (5) 638-649
    CrossrefPubMedGoogle Scholar
  • 49 Dutcher JP, Fisher RI, Weiss G , et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3 (3) 157-162
    PubMedGoogle Scholar
  • 50 Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol 1996; 14 (4) 237-243
    PubMedGoogle Scholar
  • 51 Atzpodien J, Kirchner H, Jonas U , et al; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22 (7) 1188-1194
    CrossrefPubMedGoogle Scholar
  • 52 Hongyun L, Zhihong C, Xiangqing Y , et al. Phase II study of sorafenib combined with gemcitabine and 5-fluorouracil in patients with metastatic renal cell carcinoma: preliminary results. J Clin Oncol 2009; 27 (suppl): abstr e16093
    PubMedGoogle Scholar
  • 53 Tagawa ST, Milowsky MI, Jeske S , et al. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. Am J Clin Oncol 2011; 34 (5) 443-448
    CrossrefPubMedGoogle Scholar
  • 54 Tagawa ST, Saran A, Akhtar NH , et al. Final phase II results of NCI 6981: a phase I/II study of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma. J Clin Oncol 2011; 29 (suppl): abstr e15165
    PubMedGoogle Scholar
  • 55 Bellmunt J, Trigo JM, Calvo E , et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11 (4) 350-357
    CrossrefPubMedGoogle Scholar
  • 56 Pandya SS, Mier JW, McDermott DF, Cho DC. Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int 2011; 108 (8 Pt 2) E245-E249
    CrossrefPubMedGoogle Scholar
  • 57 Michaelson MD, Zhu AX, Ryan DP , et al. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 2013; 108 (7) 1393-1401
    CrossrefPubMedGoogle Scholar
  • 58 Suarez C, Gallardo E, Rodon Ahnert J , et al. Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. ASCO Meeting Abstracts 2011; 29: e15095
    PubMedGoogle Scholar
  • 59 Jonasch E, Lal LS, Atkinson BJ , et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2011; 107 (5) 741-747
    CrossrefPubMedGoogle Scholar
  • 60 Staehler M, Haseke N, Roosen A , et al. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 2010; 15: 287-291
    CrossrefPubMedGoogle Scholar
  • 61 Michaelson MD, McDermott DF, Atkins MB , et al. Combination of antiangiogenic therapy and cytotoxic chemotherapy for sarcomatoid renal cell carcinoma. J Clin Oncol 2013; 31 (suppl):abstr 4512
    PubMedGoogle Scholar
  • 62 Jonasch E, Lal LS, Atkinson BJ , et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2011; 107 (5) 741-747
    CrossrefPubMedGoogle Scholar
  • 63 Chung EK, Posadas EM, Kasza K , et al. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2011; 34 (2) 150-154
    PubMedGoogle Scholar
  • 64 Thompson RH, Gillett MD, Cheville JC , et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101 (49) 17174-17179
    CrossrefPubMedGoogle Scholar
  • 65 Cho DC, Sosman JA, Sznol M , et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 (suppl):abstr 4505
    PubMedGoogle Scholar
  • 66 Drake CG, McDermott DF, Sznol M , et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. J Clin Oncol 2013; 31 (suppl):abstr 4514
    PubMedGoogle Scholar
  • 67 Amin A, Ernstoff MS, Infante JR , et al. A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 (suppl):abstr TPS4593
    PubMedGoogle Scholar
  • 68 Liu W, Shen SM, Zhao XY, Chen GQ. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol 2012; 3 (2) 165-178
    PubMedGoogle Scholar